Patients & Caregivers
FDA Puts Clinical Hold on Merck's Multiple Myeloma Trials Following Increased Deaths
The review panel found more deaths in multiple myeloma patients getting pembrolizumab plus pomalidomide or lenalidomide vs control groups.
TV Personality Maria Menounos Had Rare Brain Tumor
Menounos began to suspect she had brain cancer based on her own symptoms (trouble speaking) as well as her experience caring for her mother who currently has stage 4 brain cancer.
FDA Approves Expanded Use of Cooling Cap for All Solid Tumor Patients
Alopecia, or hair loss, is a common side effect of chemotherapies often used to treat treatment solid tumor cancers.
FDA Approves Diagnostic Test for Rare Blood Cancers
The FDA has approved Beckman Coulter's ClearLLab Reagents to help diagnose numerous rare blood cancers, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Pivotal Midostaurin Study in AML Patients Published in NEJM
The study observed that overall survival was significantly longer in the midostaurin group (74.7 months) compared to the placebo group (25.6 months; P = .009).
FDA Approves Subcutaneous Version of Rituximab For Several Rare Blood Cancers
The new route of administration can allow patients to be treated within minutes rather than the hours currently needed to administer rituximab intravenously.
Former Wilms' Tumor Patient Arrives at New York Jets Minicamp
Former hemihypertrophy and Wilms' tumor patient and current nose tackle Mike Pennel arrived at camp last week for his first week on the job as a New York Jet.
Lenvatinib Safe and Effective in Elderly Patients with Thyroid Cancer
There's a belief that these drugs should be withheld from elderly thyroid cancer patients due to toxicity and other medical concerns, but the results show lenvatinib is safe and effective.
Acceleron to Discontinue Development of Dalantercept for Kidney Cancer
Biotech company Accerelon announced it will discontinue development of dalantercept to treat RCC based on preliminary results from their DART Phase 2 study.
Multiple Myeloma Studies On Hold to Assess High Death Count
An increased number of deaths observed in 2 Phase 3 cancer studies involving Keytruda (pembrolizumab) in multiple myeloma patients has led Merck to pause recruitment.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.